Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.
Read Full NewsTechnique deemed safe and feasible for selected patients and better than other minimally invasive approaches
Cardiomyopathy risks interrupting cancer treatment, worsening prognosis
— News, features, and commentary about cancer-related issues
1.
According to new studies, some cancer patients can safely forego radiation therapy.
2.
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?
3.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
4.
Can Exercise Extend Survival After Breast Cancer?
5.
e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?
1.
Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation
2.
Connected Transfusion Monitoring: Advancing Safety and Efficacy in Blood Transfusion Practice
3.
Robotic Intratumoral Resection for Organ Preservation: Advances, Evidence, and Clinical Implications
4.
Blood-Cell Morphology Foundation Models: Transforming Hematological Diagnostics and Clinical Practice
5.
Unlocking the Potential of SABCS 2022: Innovative Strategies for Cancer Research
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Current Scenario of Cancer- Q&A Session to Close the Gap
5.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge